The immunology of multiple sclerosis: changing concepts, Rev Neurol (Paris). avr, vol.164, issue.2, pp.138-146, 2008. ,
Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, août, vol.34, issue.8, pp.479-86, 2013. ,
Histoire naturelle de la sclérose en plaques, Presse Médicale. mars, vol.39, issue.3, pp.359-62, 2010. ,
Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology. 15 juill, vol.83, issue.3, pp.278-86, 2014. ,
On the origin of EDSS, Mult Scler Relat Disord. mars, vol.4, issue.2, pp.95-103, 2015. ,
,
, Evidence for a two-stage disability progression in multiple sclerosis, Brain J Neurol. juill, vol.133, pp.1900-1913, 2010.
Effect of relapses on development of residual deficit in multiple sclerosis, Neurology. 9 déc, vol.61, issue.11, pp.1528-1560, 2003. ,
,
, The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability, Brain J Neurol. juill, vol.133, pp.1914-1943, 2010.
,
Impact of multiple sclerosis relapses on progression diminishes with time, Neurology, vol.17, issue.20, pp.1616-1639, 2009. ,
,
, Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study, PloS One, vol.7, issue.11, p.50101, 2012.
Onset of secondary progressive phase and long-term evolution of multiple sclerosis, J Neurol Neurosurg Psychiatry. janv, vol.85, issue.1, pp.67-75, 2014. ,
DOI : 10.1136/jnnp-2012-304333
URL : http://jnnp.bmj.com/content/jnnp/85/1/67.full.pdf
Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort, JAMA Neurol. févr, vol.72, issue.2, pp.152-160, 2015. ,
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in RelapsingRemitting Multiple Sclerosis (AFFIRM) study, Lancet Neurol. mars, vol.8, issue.3, pp.254-60, 2009. ,
,
Sustained disease-activity-free status in patients with relapsingremitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis, Lancet Neurol. avr, vol.10, issue.4, pp.329-366, 2011. ,
Baseline MRI predicts future attacks and disability in clinically isolated syndromes, Neurology. 26 sept, vol.67, issue.6, pp.968-72, 2006. ,
The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS, J Neurol. févr, vol.263, issue.2, pp.299-305, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01886308
,
, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry. févr, vol.62, issue.2, pp.112-120, 1997.
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, Brain J Neurol. avr, vol.126, pp.770-82, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00427394
,
20-year follow-up of patients with relapse onset of multiple sclerosis, Brain J Neurol. mars, vol.131, pp.808-825, 2008. ,
Demographic and clinical characteristics of malignant multiple sclerosis, Neurology. 7 juin, vol.76, issue.23, pp.1996-2001, 2011. ,
,
, Characterising aggressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.84, issue.11, pp.1192-1200, 2013.
Disability progression in aggressive multiple sclerosis, Mult Scler J. 20 juin, p.1352458516653273, 2016. ,
,
, A study of patients with aggressive multiple sclerosis at disease onset
, Neuropsychiatr Dis Treat, vol.12, pp.1907-1919, 2016.
Induction and escalation therapies in multiple sclerosis, Anti-Inflamm Anti-Allergy Agents Med Chem, vol.14, issue.1, pp.26-34, 2015. ,
Should MS be treated by escalation or induction therapy?, Coll Antropol. mars, vol.38, issue.1, pp.385-93, 2014. ,
Induction therapy for patients with multiple sclerosis: why? When? How?, CNS Drugs. juin, vol.27, issue.6, pp.403-412, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00877114
Treatment of acute lymphoblastic leukemia, N Engl J ,
, Med. 12 janv, vol.354, issue.2, pp.166-78, 2006.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome, J Neurol. mars, vol.244, issue.3, pp.153-162, 1997. ,
,
, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet Lond Engl. 21 déc, vol.360, issue.9350, pp.2018-2043, 2002.
,
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis, J Neuroimmunol. 15 janv, vol.278, pp.277-286, 2015. ,
,
, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry. févr, vol.62, issue.2, pp.112-120, 1997.
Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone, J Neuroimmunol. déc, vol.13, issue.2, pp.175-81, 1986. ,
,
, Effects of mitoxantrone on multiple sclerosis patients" lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10, Eur Neurol, vol.49, issue.3, pp.137-178, 2003.
Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells ,
, Immunopharmacol Immunotoxicol. févr, vol.34, issue.1, pp.36-41, 2012.
Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone, Cancer Res. 15 sept, vol.50, issue.18, pp.5813-5821, 1990. ,
Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice, J Immunol Baltim Md, vol.136, issue.8, pp.2747-54, 1950. ,
Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis, Arch Neurol, vol.63, issue.11, pp.1572-1580, 2006. ,
Pharmacokinetics and metabolism of mitoxantrone. A review, Clin Pharmacokinet. mai, vol.18, issue.5, pp.365-80, 1990. ,
Evidence ep ort: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis, Neurology. 4 mai, vol.74, issue.18, pp.1463-70, 2010. ,
Use of mitoxantrone to treat multiple sclerosis, Multiple Sclerosis Therapeutics, pp.403-430 ,
Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study, Neurology. 7 juin, vol.86, issue.23, pp.2203-2210, 2016. ,
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?, Mult Scler Houndmills Basingstoke Engl. avr, vol.21, issue.5, pp.642-647, 2015. ,
,
, European database for multiple sclerosis, J Neurol Neurosurg Psychiatry. août, vol.55, issue.8, pp.671-677, 1992.
Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment, Mult Scler. 1 juin, vol.13, issue.5, pp.626-657, 2007. ,
,
, Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry. janv, vol.79, issue.1, pp.52-58, 2008.
,
, Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up, Eur J Neurol Off J Eur Fed Neurol Soc. nov, vol.14, issue.11, pp.1281-1288, 2007.
,
, Increasing incidence of multiple sclerosis among women in Lorraine
, Mult Scler Houndmills Basingstoke Engl. sept, vol.13, issue.8, pp.962-969, 2007.
,
, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol. mars, vol.13, issue.3, pp.227-258, 1983.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology. avr, vol.46, issue.4, pp.907-918, 1996. ,
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol. juill, vol.50, issue.1, pp.121-128, 2001. ,
,
, Diagnostic criteria for multiple sclerosis: 2005 revisions to the « McDonald Criteria
, Ann Neurol. déc, vol.58, issue.6, pp.840-846, 2005.
,
, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol. févr, vol.69, issue.2, pp.292-302, 2011.
, et J Neurol. déc, vol.136, pp.3609-3626, 2013.
,
, Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
, Mult Scler J. 1 août, vol.22, issue.9, pp.1215-1238, 2016.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience, J Neurol Neurosurg Psychiatry, vol.85, issue.10, pp.1116-1137, 2014. ,
,
, Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial, Neurology. 10 mars, vol.84, issue.10, pp.981-989, 2015.
,
, Alemtuzumab more effective than interferon ?-1a at 5-year follow-up of CAMMS223 clinical trial, Neurology. 3 avr, vol.78, issue.14, pp.1069-78, 2012.
,
, Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis, JAMA. 18 juill, vol.308, issue.3, pp.247-56, 2012.
,
, Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. 6 avr, 2016.
Influence of treatments in multiple sclerosis disability: a cohort study, Mult Scler Houndmills Basingstoke Engl. avr, vol.21, issue.4, pp.433-474, 2015. ,
,
, The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability, Brain. juill, vol.133, issue.7, pp.1914-1943, 2010.
,
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15, J Neurol Neurosurg Psychiatry, vol.86, issue.11, pp.1202-1209, 2015. ,
,
Predictors of long-term disability accrual in relapse-onset multiple sclerosis ,
, Ann Neurol. juill, vol.80, issue.1, pp.89-100, 2016.
,
, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-71, 2009.
Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, issue.20, pp.1430-1438, 2000. ,